Conversely, vandetanib, a TKI targeting vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR)-dependant signaling, recently completed a phase II study in GIST patients deficient in the expression of succinate dehydrogenase (SDH), however, with no partial or complete responses observed in nine patients, the authors concluded vandetanib lacked activity in these patients [11]. Here, EGFR is linked to gastrointestinal stromal tumor.